Please assess the completion status of the following clinical trial:

Trial Title: Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children (age \<18) with documented positive TST (or in the absence of TST, a positive QFT or T-Spot) and prescribed 9INH for LTBI for the following indications:~  1. HIV positive (TST \>5 mm or QFT+)~ 2. Age 5 or less (TST \>5 mm or QFT+)~ 3. Other reason for immuno-compromised state - such as therapy for malignancy or post-transplant (TST \>5 mm or QFT+)~ 4. Contact: with adult or adolescent with active contagious pulmonary TB. (TST \>5 mm or QFT +)~ 5. Have both of the following factors if TST = 10-14mm or QFT + or one factor if TST \>15mm :~     1. Arrival in Canada, Australia, or Saudi Arabia in the past 2 years from countries with estimated annual incidence of active TB greater than 100 per 100,000~    2. Body mass index (BMI) less than 10th percentile for their age~Exclusion Criteria:~* Patients who were contacts of TB cases known to be resistant to Isoniazid, Rifampin, or both.~* Known HIV-infected individuals on anti-retroviral agents whose efficacy would be substantially reduced by Rifampin, unless therapy can safely be changed to agents not affected by Rifampin.~* Pregnant women - Rifampin and Isoniazid are considered safe in pregnancy but therapy is usually deferred until 2-3 months post-partum to avoid fetal risk and the potential for increased hepato-toxicity immediately post partum.~* Patients on any medication with clinically important drug interactions with Isoniazid or Rifampin, which their physician believes would make either arm contra-indicated.~* Patients with a history of allergy/hypersensitivity to Isoniazid or to Rifampin, Rifabutin, or Rifapentine.~* Patients with active TB. Patients initially suspected to have active TB can be randomized once this has been excluded.~* Prior complete LTBI therapy or if children have taken \>1 week and are still taking the treatment. Children will be eligible if they took an incomplete LTBI therapy (less than 80% of recommended total dose) but \> 6 months ago.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Isoniazid (Type: ACTIVE_COMPARATOR): The standard therapy will be daily self-administered INH, 10-15 mg/kg/day (max=300mg/day) for 9 months (9INH).
- Rifampin (Type: ACTIVE_COMPARATOR): The experimental arm will be daily self-administered RIF 10-20 mg/kg/day for 4 months (4RIF).

Based on this trial design, predict the completion outcome and termination type (if applicable).